Australian biotech market today 14.04.09
Tuesday, 14 April, 2009
The overall healthcare index was up on today’s trading at 2.30pm, following the trend of the rest of the indices. The All Ordinaries is up 2.5 per cent.
Cellestis (ASX:CST) is up 19c to $2.55 on the news that its TB diagnostic QuantiFERON-TB Gold In-Tube has received regulatory approval in Japan.
ChemGenex (ASX:CXS) is continuing to enjoy gains after announcing it had raised $10 million in secondary financing last week, up 4c to 46c.
Acrux (ASX:ACR) is up 2c to 65c, as is Biota (ASX:BTA) to 66c. Mesoblast (ASX:MSB) is up 5c to 85c.
Cochlear (ASX:COH) is up 68c, CSL (ASX:CSL) is down 11c and ResMed (ASX:RMD) is up 4c.
Pharmaxis (ASX:PXS) is down a steep 13c to $2.02 on reasonable volumes, as is Novogen (ASX:NRT), down 13.5 per cent to 48c. QRxPharma (ASX:QRX) is up 4c to 32c.
Progen (ASX:PGL) is up 3.8 per cent to 95c while Probiotec (ASX:PBP) is again enjoying healthy rises, up 6.2 per cent to $1.89.
Living Cell Technologies (ASX:LCT) is down 3.5c to 12c, while there has been some rare movement with LabTech Systems (ASX:LBT), up a cent to 14.5.
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
